monomethyl fumarate monomethyl fumarate monomethyl fumarate, sold under the brand name bafiertam is a medication for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. it is taken by mouth. monomethyl fumarateclinical datatrade namesbafiertamlicense data us dailymed: monomethyl_fumarate routes ofadministrationby mouthatc codenonelegal statuslegal status us: ℞-only identifiers iupac name (2e)-4-methoxy-4-oxobut-2-enoic acid cas number2756-87-8pubchem cid5369209drugbankdb14219chemspider4520322unii45iub1px8rkeggd11492chebichebi:167450chemblchembl589586echa infocard100.018.557 chemical and physical dataformulac5h6o4molar mass130.099 g·mol−13d model (jsmol)interactive image smiles coc(=o)c=cc(=o)o inchi inchi=1s/c5h6o4/c1-9-5(8)3-2-4(6)7/h2-3h,1h3,(h,6,7)/b3-2+key:nkhavtqwnuwkeo-nscuhmnnsa-n the most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea. it was approved for medical use in the united states in april 2020. pharmacology monomethyl fumarate alters the nfe2l2 (nuclear factor erythroid 2-related factor 2) transcription factor. nfe2l2 (or nrf2) is a basic leucine zipper (bzip) protein that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. several drugs that stimulate the nfe2l2 pathway are being studied for treatment of diseases that are caused by oxidative stress. two precursors are also approved: dimethyl fumarate (brand name tecfidera), diroximel fumarate (brand name vumerity), approved by the fda in october 2019. society and culture names monomethyl fumarate is the international nonproprietary name (inn).